Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
11/1/24 Novo Nordisk (NVO) Semaglutide (NASH) for Non-Alcoholic Steatohepatitis (NASH) Subscribers Only Subscribers Only Subscribers Only
10/31/24 Lexicon Pharmaceuticals (LXRX) Inpefa for Diabetes Mellitus, Type I Subscribers Only Subscribers Only Subscribers Only
10/30/24 Corcept Therapeutics (CORT) Relacorilant for Cushing's Syndrome Subscribers Only Subscribers Only Subscribers Only
10/29/24 GlycoMimetics (GLYC) Uproleselan for Acute Myelogenous Leukemia (AML) Subscribers Only Subscribers Only Subscribers Only
10/29/24 Lexicon Pharmaceuticals (LXRX) Inpefa for Diabetes Mellitus, Type I Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
03/01/2025 - 04/30/2024 Subscribers Only Subscribers Only Trial Announcement - Data Monitoring Board Analysis
09/12/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/16/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/30/2024 Subscribers Only Subscribers Only Progress Update - Development Review
11/07/2024 Subscribers Only Subscribers Only Trial Data - Top-Line Results